-
Uncategorized1 month ago
Intercept’s next-gen FXR agonist fails Phase 2 in latest setback for Italian-owned pharma
Intercept Pharmaceuticals’ attempt at creating a next-generation FXR agonist for certain forms of liver inflammation appears to have ended. The drug developer’s INT-787 showed “no clear...
-
Uncategorized1 month ago
Pfizer’s Albert Bourla says he has no mega-merger plans
The most candid man in pharma strikes again. When asked on Tuesday’s earnings call whether Pfizer would consider a “transformative M&A” deal in the near or...
-
Uncategorized1 month agoSTAT+: Pharma’s reputation among patient groups rose last year, but concerns remain over access and pricing
The pharmaceutical industry saw its reputation among patient groups inch up last year, but the rise masks fresh concerns about the extent to which some companies...
-
Uncategorized1 month agoSTAT+: A new attack on AMA’s billing codes
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your...
-
Uncategorized1 month ago
BioNTech to scale down manufacturing, over 1,800 jobs on the line
BioNTech is making big cuts to its manufacturing footprint. The German company said in its first-quarter earnings release that up to 1,860 manufacturing staff could be...
-
Uncategorized1 month agoViridian data lift prospects for thyroid eye disease drug
Whereas earlier Phase 3 results disappointed Wall Street, new findings in people with “chronic” disease were viewed by analysts as much more competitive with Amgen’s Tepezza.
-
Uncategorized1 month ago
Pfizer is a 2029 story but Q126 lays foundation for growth
A legal settlement has put wind behind Pfizer’s sales into 2029—at which point key obesity moves will take the helm.
-
Uncategorized1 month ago
Second life for gene therapy; Takeda Phase 2/3 win; UK cancer biotech’s $83M
A blood test might predict who will respond to Wegovy; Viridian’s thyroid eye disease drug wins another Phase 3; Ideaya drops two GSK-returned assets. 🧬 Second...
-
Uncategorized1 month ago
After Arcellx buyout close, Gilead trims 108 jobs at CAR-T biotech’s Redwood City outpost
With Gilead’s $7.8 billion buyout of Arcellx complete, the California pharma is consolidating some of the workforce at the acquired company.
-
Uncategorized1 month ago
Swiss manufacturing, biotech industry so far unfazed by geopolitics
BASEL, Switzerland — Pharma manufacturing in Switzerland appears to be unperturbed by the threat of tariffs, but it might take several years before the impact of...
